{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T19:09:24Z","timestamp":1789412964040,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jcyt.2025.10.001","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:56:08Z","timestamp":1760223368000},"page":"101991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A differentiated and durable allogeneic strategy applicable to cell therapies"],"prefix":"10.1016","volume":"28","author":[{"given":"Utsav","family":"Jetley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7773-5222","authenticated-orcid":false,"given":"Ishina","family":"Balwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0403-9948","authenticated-orcid":false,"given":"Palak","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allie","family":"Luther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivy","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithila","family":"Saravanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzhan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgun","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-8702","authenticated-orcid":false,"given":"Bo W.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7479-2237","authenticated-orcid":false,"given":"Dai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2275-3383","authenticated-orcid":false,"given":"Birgit","family":"Schultes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Prodeus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1065-591X","authenticated-orcid":false,"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2025.10.001_bib0001","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0002","doi-asserted-by":"crossref","DOI":"10.1007\/s40291-025-00771-z","article-title":"Obecabtagene autoleucel: first approval","author":"Lee","year":"2025","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0003","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0004","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-024-08452-3","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M(+) diffuse midline gliomas","author":"Monje","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0005","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0006","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03449-x","article-title":"Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma","author":"Quintarelli","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0007","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1016\/S2665-9913(24)00377-1","article-title":"CAR T-cell therapy in autoimmune diseases: where are we and where are we going?","volume":"7","author":"Scherlinger","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0008","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","article-title":"Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy","volume":"4","author":"Hernandez","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0009","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1199145","article-title":"Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy","volume":"14","author":"Lv","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0011","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0012","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/319675a0","article-title":"Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy","volume":"319","author":"K\u00e4rre","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0013","doi-asserted-by":"crossref","first-page":"eabg8027","DOI":"10.1126\/scitranslmed.abg8027","article-title":"CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function","volume":"14","author":"Ruggiero","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0014","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1038\/s41467-023-40344-4","article-title":"Simultaneous inhibition of DNA-PK and Pol\u03f4 improves integration efficiency and precision of genome editing","volume":"14","author":"Wimberger","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0015","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41587-023-01888-4","article-title":"High-efficiency transgene integration by homology-directed repair in human primary cells using DNA-PKcs inhibition","volume":"42","author":"Selvaraj","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0016","first-page":"10","article-title":"The new kid on the block: HLA-C, a key regulator of natural killer cells in viral immunity","author":"Vollmers","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0017","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/TP.0000000000004420","article-title":"Pathways of antigen recognition by T cells in allograft rejection","volume":"107","author":"Carnel","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1436233","article-title":"Implications of MHC-restricted immunopeptidome in transplantation","volume":"15","author":"Zhanzak","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0019","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood.2022019333","article-title":"Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells","volume":"142","author":"Vavassori","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0020","first-page":"367","article-title":"CRISPR-engineered T cells in patients with refractory cancer","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0021","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1038\/s41587-022-01377-0","article-title":"Frequent aneuploidy in primary human T cells after CRISPR-Cas9 cleavage","volume":"40","author":"Nahmad","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2023.08.041","article-title":"Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells","volume":"186","author":"Tsuchida","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0023","doi-asserted-by":"crossref","first-page":"TPS6586","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS6586","article-title":"A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed\/refractory acute myeloid leukemia (AMpLify)","volume":"42","author":"Daver","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0024","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0025","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.jcyt.2024.05.022","article-title":"Considerations for the development of iPSC-derived cell therapies: a review of key challenges by the JSRM-ISCT iPSC Committee","volume":"26","author":"Madrid","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0026","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40291-024-00708-y","article-title":"Lifileucel: first approval","volume":"28","author":"Keam","year":"2024","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0027","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40291-024-00749-3","article-title":"Afamitresgene autoleucel: first approval","volume":"28","author":"Keam","year":"2024","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0028","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40291-023-00648-z","article-title":"Tabelecleucel: first approval","volume":"27","author":"Keam","year":"2023","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0029","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41571-024-00959-y","article-title":"Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks","volume":"22","author":"Diorio","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0030","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2014-01-514752","article-title":"Current issues in chronic graft-versus-host disease","volume":"124","author":"Soci\u00e9","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0031","article-title":"Rejection resistant CD30.CAR-modified Epstein-Barr virus-specific T cells as an off-the-shelf platform for CD30(+) lymphoma","volume":"32","author":"Quach","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0032","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2022-160244","article-title":"CD30.CAR-modified Epstein-Barr virus-specific t cells (CD30.CAR EBVERSUSTs) provide a safe and effective off-the-shelf therapy for patients with CD30-positive lymphoma","volume":"140","author":"Quach","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0033","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0034","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/blood-2024-203546","volume":"144","author":"Diorio","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0035","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.1200\/JCO.2024.42.16_suppl.7025","article-title":"A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed\/refractory B cell non-Hodgkin lymphoma (r\/r B-NHL): updated phase 1 results from the ANTLER trial","volume":"42","author":"Hu","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0036","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0037","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood-2021-150609","article-title":"Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in patients with relapsed\/refractory B-cell malignancies","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0038","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-140641","article-title":"Universal: an allogeneic first-in-human study of the anti-BCMA ALLO-715 and the anti-CD52 ALLO-647 in relapsed\/refractory multiple myeloma","volume":"136","author":"Mailankody","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0039","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-cancerbio-062822-023316","article-title":"Allogeneic CAR T cell therapy for cancer","volume":"8","author":"Sasu","year":"2024","journal-title":"Annu Rev Cancer Biol"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0040","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2021-145572","article-title":"Universal updated phase 1 data validates the feasibility of allogeneic anti-BCMA ALLO-715 therapy for relapsed\/refractory multiple myeloma","volume":"138","author":"Mailankody","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0041","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1038\/s41467-022-30896-2","article-title":"Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing","volume":"13","author":"Jo","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0042","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41467-023-37785-2","article-title":"Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice","volume":"14","author":"Hu","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2024.06.011","article-title":"Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies","volume":"31","author":"Hammer","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0044","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41551-024-01282-8","article-title":"Ablation of FAS confers allogeneic CD3(-) CAR T cells with resistance to rejection by T cells and natural killer cells","volume":"8","author":"Menegatti","year":"2024","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0045","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41587-020-0601-5","article-title":"Engineered off-the-shelf therapeutic T cells resist host immune rejection","volume":"39","author":"Mo","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"suppl 9","key":"10.1016\/j.jcyt.2025.10.001_bib0046","article-title":"Preclinical evaluation of ALLO-329: allogeneic CD19 CAR T cells expressing an anti-rejection CD70 CAR for the treatment of autoimmune diseases","volume":"76","author":"Zhang","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0047","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0048","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0049","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2025.10.001_bib0050","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925008655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925008655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T07:19:50Z","timestamp":1780816790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925008655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1465324925008655"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.10.001","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A differentiated and durable allogeneic strategy applicable to cell therapies","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101991"}}